Clinical Trials Directory

Trials / Unknown

UnknownNCT01496833

Total Endovascular Aortic Arch Re-construction Study(TEARS)

Total Endovascular Aortic Arch Re-construction Study(TEARS)------China's Registry

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Xijing Hospital · Academic / Other
Sex
All
Age
12 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the short to mid term efficacy and safety of a newly-developed branched stent graft in patients who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Detailed description

Aneurysms and dissection involving the ascending aorta and aortic arch have historically been treated with open surgical techniques, requiring cardiopulmonary bypass and deep hypothermic circulatory arrest (DHCA). Despite increasing experience and refinement of these procedures, there remains a substantial rate of morality and morbidity. Total endovascular aortic arch and ascending aorta repair is one of the ultimate solutions of these diseases. However, this approach requires extensive technique and new device development. The goal of total endoluminal stent grafting is to re-construct the ascending aorta and aortic arch to cover the primary entry tear of the dissection and to remodel the aorta.Recently, branch and fenestrated stent-grafts has been developed to treat complex ascending and aortic arch disease, which was previously considered to be contraindicated for endovascular repair. This study aims to investigate the short to mid term efficacy and safety of a newly-developed branched stent graft in patients who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al. Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (\>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study designs to enroll 50 patients to be monitored for 24 months.

Conditions

Interventions

TypeNameDescription
DEVICEAnkura Branched/Fenestrated Stent GraftAnkura Branched/Fenestrated Stent Graft(Lifetech Scientific Co.,LTD.,Shenzhen, China)

Timeline

Start date
2015-01-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2011-12-21
Last updated
2016-01-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01496833. Inclusion in this directory is not an endorsement.